Principal Investigator Dr. Joel Saper is conducting a clinical research study evaluating an investigational nasal spray medication for the treatment of migraine headaches. The investigational medication is a new formulation of intranasal sumatriptan. Intranasal sumatriptan is an FDA-approved medication for the treatment of acute migraine. Researchers want to learn if a new formulation will begin to work faster to relieve migraine.
To qualify for this study, individuals must:
- be between 18 and 75 years of age
- experience 2–8 headaches per month
- meet other study eligibility criteria
If you qualify, you will receive study-required exams and study medication at no cost to you. During the study, you will treat two migraine headaches with either active medication or placebo. In addition, you may be compensated for your time and travel expenses.
Please complete the following profile and a Research Nurse will contact you.